Effects of antipsychotic drugs on neurites relevant to schizophrenia treatment
Although antipsychotic drugs are mainly used for treating schizophrenia, they are widely used for treating various psychiatric diseases in adults, the elderly, adolescents and even children. Today, about 1.2% of the worldwide population suffers from psychosis and related disorders, which translates...
Saved in:
| Published in | Medicinal research reviews Vol. 39; no. 1; pp. 386 - 403 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley Subscription Services, Inc
01.01.2019
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0198-6325 1098-1128 1098-1128 |
| DOI | 10.1002/med.21512 |
Cover
| Abstract | Although antipsychotic drugs are mainly used for treating schizophrenia, they are widely used for treating various psychiatric diseases in adults, the elderly, adolescents and even children. Today, about 1.2% of the worldwide population suffers from psychosis and related disorders, which translates to about 7.5 million subjects potentially targeted by antipsychotic drugs. Neurites project from the cell body of neurons and connect neurons to each other to form neural networks. Deficits in neurite outgrowth and integrity are implicated in psychiatric diseases including schizophrenia. Neurite deficits contribute to altered brain development, neural networking and connectivity as well as symptoms including psychosis and altered cognitive function. This review revealed that (1) antipsychotic drugs could have profound effects on neurites, synaptic spines and synapse, by which they may influence and regulate neural networking and plasticity; (2) antipsychotic drugs target not only neurotransmitter receptors but also intracellular signaling molecules regulating the signaling pathways responsible for neurite outgrowth and maintenance; (3) high doses and chronic administration of antipsychotic drugs may cause some loss of neurites, synaptic spines, or synapsis in the cortical structures. In addition, confounding effects causing neurite deficits may include elevated inflammatory cytokines and antipsychotic drug‐induced metabolic side effects in patients on chronic antipsychotic therapy. Unraveling how antipsychotic drugs affect neurites and neural connectivity is essential for improving therapeutic outcomes and preventing aversive effects for patients on antipsychotic drug treatment. |
|---|---|
| AbstractList | Although antipsychotic drugs are mainly used for treating schizophrenia, they are widely used for treating various psychiatric diseases in adults, the elderly, adolescents and even children. Today, about 1.2% of the worldwide population suffers from psychosis and related disorders, which translates to about 7.5 million subjects potentially targeted by antipsychotic drugs. Neurites project from the cell body of neurons and connect neurons to each other to form neural networks. Deficits in neurite outgrowth and integrity are implicated in psychiatric diseases including schizophrenia. Neurite deficits contribute to altered brain development, neural networking and connectivity as well as symptoms including psychosis and altered cognitive function. This review revealed that (1) antipsychotic drugs could have profound effects on neurites, synaptic spines and synapse, by which they may influence and regulate neural networking and plasticity; (2) antipsychotic drugs target not only neurotransmitter receptors but also intracellular signaling molecules regulating the signaling pathways responsible for neurite outgrowth and maintenance; (3) high doses and chronic administration of antipsychotic drugs may cause some loss of neurites, synaptic spines, or synapsis in the cortical structures. In addition, confounding effects causing neurite deficits may include elevated inflammatory cytokines and antipsychotic drug‐induced metabolic side effects in patients on chronic antipsychotic therapy. Unraveling how antipsychotic drugs affect neurites and neural connectivity is essential for improving therapeutic outcomes and preventing aversive effects for patients on antipsychotic drug treatment. Although antipsychotic drugs are mainly used for treating schizophrenia, they are widely used for treating various psychiatric diseases in adults, the elderly, adolescents and even children. Today, about 1.2% of the worldwide population suffers from psychosis and related disorders, which translates to about 7.5 million subjects potentially targeted by antipsychotic drugs. Neurites project from the cell body of neurons and connect neurons to each other to form neural networks. Deficits in neurite outgrowth and integrity are implicated in psychiatric diseases including schizophrenia. Neurite deficits contribute to altered brain development, neural networking and connectivity as well as symptoms including psychosis and altered cognitive function. This review revealed that (1) antipsychotic drugs could have profound effects on neurites, synaptic spines and synapse, by which they may influence and regulate neural networking and plasticity; (2) antipsychotic drugs target not only neurotransmitter receptors but also intracellular signaling molecules regulating the signaling pathways responsible for neurite outgrowth and maintenance; (3) high doses and chronic administration of antipsychotic drugs may cause some loss of neurites, synaptic spines, or synapsis in the cortical structures. In addition, confounding effects causing neurite deficits may include elevated inflammatory cytokines and antipsychotic drug-induced metabolic side effects in patients on chronic antipsychotic therapy. Unraveling how antipsychotic drugs affect neurites and neural connectivity is essential for improving therapeutic outcomes and preventing aversive effects for patients on antipsychotic drug treatment.Although antipsychotic drugs are mainly used for treating schizophrenia, they are widely used for treating various psychiatric diseases in adults, the elderly, adolescents and even children. Today, about 1.2% of the worldwide population suffers from psychosis and related disorders, which translates to about 7.5 million subjects potentially targeted by antipsychotic drugs. Neurites project from the cell body of neurons and connect neurons to each other to form neural networks. Deficits in neurite outgrowth and integrity are implicated in psychiatric diseases including schizophrenia. Neurite deficits contribute to altered brain development, neural networking and connectivity as well as symptoms including psychosis and altered cognitive function. This review revealed that (1) antipsychotic drugs could have profound effects on neurites, synaptic spines and synapse, by which they may influence and regulate neural networking and plasticity; (2) antipsychotic drugs target not only neurotransmitter receptors but also intracellular signaling molecules regulating the signaling pathways responsible for neurite outgrowth and maintenance; (3) high doses and chronic administration of antipsychotic drugs may cause some loss of neurites, synaptic spines, or synapsis in the cortical structures. In addition, confounding effects causing neurite deficits may include elevated inflammatory cytokines and antipsychotic drug-induced metabolic side effects in patients on chronic antipsychotic therapy. Unraveling how antipsychotic drugs affect neurites and neural connectivity is essential for improving therapeutic outcomes and preventing aversive effects for patients on antipsychotic drug treatment. |
| Author | Huang, Xu‐Feng Song, Xueqin |
| Author_xml | – sequence: 1 givenname: Xu‐Feng orcidid: 0000-0002-5895-2253 surname: Huang fullname: Huang, Xu‐Feng email: xhuang@uow.edu.au organization: University of Wollongong – sequence: 2 givenname: Xueqin surname: Song fullname: Song, Xueqin organization: Zhengzhou University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29785841$$D View this record in MEDLINE/PubMed |
| BookMark | eNp10ctOAyEUBmBiNFovC1_ATOJGF1UuQ2GWRusl8bLRNWHowWKmUIHR1KcXbd0YXUHI9_8h52yjdR88ILRP8AnBmJ7OYHJCCSd0DQ0IbuSQECrX0QCTch8xyrfQdkovGJOC2Cbaoo2QXNZkgO7H1oLJqQq20j67eVqYacjOVJPYP5dnX3noo8uQqggdvBVU5VAlM3UfYT6N4J2ucgSdZ-DzLtqwukuwtzp30NPl-PH8enj7cHVzfnY7NIwzOhSaj7gRtMV2xExtassJB4Mnpm1lQ6TVwpJa8NYKalhtDJvIRrZMNFY2LW7YDjpa9s5jeO0hZTVzyUDXaQ-hT4rimoq6wZgVeviLvoQ--vI7RUktBWNM4KIOVqpvyzjVPLqZjgv1M6kCTpfAxJBSBKuMyzq74HPUrlMEq69dqK_w9y5K4vhX4qf0L7tqf3cdLP6H6m58sUx8AjsHl5c |
| CitedBy_id | crossref_primary_10_1093_schbul_sbz060 crossref_primary_10_1038_s41598_020_75356_3 crossref_primary_10_1007_s00213_023_06515_3 crossref_primary_10_3389_fnins_2020_579139 crossref_primary_10_3390_biomedicines10123183 crossref_primary_10_1016_j_neuro_2021_10_007 crossref_primary_10_1016_j_abb_2020_108279 crossref_primary_10_1002_pcn5_71 crossref_primary_10_3390_biom14060688 crossref_primary_10_3390_ijms22115511 crossref_primary_10_1016_j_schres_2023_07_027 crossref_primary_10_1038_s41398_020_01155_z crossref_primary_10_1176_appi_focus_20200051 crossref_primary_10_1016_j_schres_2023_02_029 crossref_primary_10_1186_s13041_021_00729_2 crossref_primary_10_1016_j_jsps_2024_102205 crossref_primary_10_7554_eLife_57519 crossref_primary_10_1016_j_jsbmb_2021_105863 crossref_primary_10_3389_fncel_2019_00467 crossref_primary_10_3389_fnins_2020_00642 crossref_primary_10_1016_j_apmt_2022_101481 crossref_primary_10_1177_0706743720966459 crossref_primary_10_1021_acsabm_2c00679 crossref_primary_10_1038_s41386_022_01512_0 crossref_primary_10_3389_fnins_2018_00743 crossref_primary_10_1002_jcb_28455 crossref_primary_10_1016_j_jpsychires_2020_09_012 crossref_primary_10_1002_mds_28046 crossref_primary_10_1002_syn_22276 crossref_primary_10_1111_jnc_15225 crossref_primary_10_1016_j_bmcl_2021_127909 crossref_primary_10_1186_s13034_024_00743_x |
| Cites_doi | 10.1016/j.psychres.2010.02.009 10.1007/978-3-642-25758-2_10 10.3389/fncel.2013.00260 10.1186/s13195-015-0102-9 10.1016/j.schres.2011.06.029 10.1016/j.tig.2010.05.007 10.1038/sj.mp.4000581 10.1016/j.neubiorev.2013.06.001 10.3389/fncel.2010.00011 10.1523/JNEUROSCI.5029-13.2015 10.1586/ern.11.76 10.1086/342734 10.1073/pnas.1012621108 10.1111/j.1471-4159.2011.07590.x 10.1038/sj.npp.1300710 10.1038/npp.2009.10 10.1016/j.biopsych.2006.03.065 10.1073/pnas.0802615105 10.1016/j.neuron.2004.11.011 10.1074/jbc.M703298200 10.2174/1389450110607011421 10.1038/sj.npp.1301511 10.1146/annurev.pharmtox.011008.145634 10.1016/S0006-3223(00)01058-1 10.1016/j.mcn.2004.08.001 10.1016/j.biopsych.2005.11.002 10.1016/j.biopsycho.2007.10.011 10.1523/JNEUROSCI.16-07-02157.1996 10.1073/pnas.0504262102 10.1016/j.jaac.2009.09.003 10.1016/j.brainres.2009.09.008 10.1016/j.schres.2007.12.474 10.1124/pr.107.00107 10.1073/pnas.1113793109 10.1111/jnc.14107 10.1001/archgenpsychiatry.2008.514 10.1038/sj.mp.4001886 10.1016/0006-3223(92)90311-M 10.1016/j.tins.2009.05.007 10.1016/j.pnpbp.2008.09.020 10.1074/jbc.M801713200 10.1001/archpsyc.57.1.65 10.1038/nrd1346 10.1002/1096-8628(20010115)98:2<161::AID-AJMG1025>3.0.CO;2-B 10.1001/jamapsychiatry.2014.2178 10.1038/nrendo.2011.156 10.1016/S0006-3223(01)01207-0 10.1016/j.clinthera.2005.07.017 10.1016/j.biopsych.2015.02.008 10.1016/j.neuropharm.2017.01.034 10.1016/j.biopsych.2004.01.023 10.1002/syn.21634 10.1016/S0022-3565(24)36394-3 10.1016/j.neures.2011.07.1824 10.1016/j.euroneuro.2013.06.005 10.1016/j.schres.2006.11.009 10.1038/npp.2010.50 10.1038/tp.2012.97 10.1016/j.neuron.2014.11.007 10.1523/JNEUROSCI.1689-07.2007 10.1007/s11064-015-1757-0 10.1016/S0165-0173(99)00048-X 10.1016/S0920-9964(02)00201-3 10.1523/JNEUROSCI.15-05-03429.1995 10.1038/nrn2870 10.1038/mp.2016.200 10.1016/j.pnpbp.2010.10.025 10.1016/S0306-4522(01)00256-1 10.1152/physrev.1998.78.1.189 10.2174/1566524015666150330143008 10.1177/0269881109358199 10.1038/261717a0 10.1038/nn.2741 10.1385/JMN:27:1:043 10.1016/j.mcn.2006.05.007 10.1038/sj.mp.4001682 10.1001/archpsyc.62.11.1205 10.1038/sj.mp.4001751 10.1016/j.schres.2004.05.014 10.1111/obr.12638 10.1038/nrn.2015.19 10.1038/sj.mp.4001434 10.1056/NEJMoa061240 10.1038/nature09552 10.1016/j.conb.2007.01.009 10.1001/archpsyc.59.7.663 10.1176/appi.ajp.158.9.1367 10.1016/j.tins.2010.01.001 10.1097/ALN.0000000000000579 10.1358/dot.2007.43.9.1088821 10.1038/tp.2015.136 10.1523/JNEUROSCI.4314-06.2007 10.1016/j.neuron.2014.06.007 10.1002/jnr.23390 10.1038/nm1418 10.1038/ncomms10118 10.1073/pnas.0704031104 10.1016/j.celrep.2013.02.011 10.1016/j.neuropharm.2011.05.022 10.1002/dneu.22391 10.1124/pr.110.002642 10.1038/nm.2315 10.1038/sj.mp.4002066 10.1016/j.euroneuro.2015.01.014 10.1016/j.pneurobio.2011.04.003 10.1093/schbul/sbs076 10.1038/mp.2014.66 10.1038/mp.2015.77 10.1038/nrn2392 10.1038/nn.3542 10.1016/j.neuron.2007.03.028 10.1097/ALN.0b013e3181ed09a2 10.1073/pnas.0905884106 10.1016/j.neuron.2012.09.013 10.1046/j.1471-4159.2003.01638.x 10.1016/j.biopsych.2013.09.012 10.1007/s00115-014-4027-5 10.1038/mp.2012.137 10.1126/science.1255514 10.1007/s00213-010-1954-0 10.1038/srep19581 10.1016/j.pscychresns.2013.09.013 10.1038/nrd2571 10.1001/archgenpsychiatry.2012.169 10.1523/JNEUROSCI.1086-05.2005 10.1093/cercor/4.1.78 10.1038/nrdp.2015.67 10.1038/sj.mp.4001985 10.1038/srep39209 10.1016/j.schres.2012.07.014 10.4088/JCP.14m09740 10.1001/jama.2011.1360 10.1523/JNEUROSCI.22-14-06092.2002 10.1056/NEJMoa051688 |
| ContentType | Journal Article |
| Copyright | 2018 Wiley Periodicals, Inc. Copyright © 2018 Wiley Periodicals, Inc. |
| Copyright_xml | – notice: 2018 Wiley Periodicals, Inc. – notice: Copyright © 2018 Wiley Periodicals, Inc. |
| DBID | AAYXX CITATION NPM K9. 7X8 |
| DOI | 10.1002/med.21512 |
| DatabaseName | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic CrossRef PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1098-1128 |
| EndPage | 403 |
| ExternalDocumentID | 29785841 10_1002_med_21512 MED21512 |
| Genre | reviewArticle Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: Innovative Talents Project of Henan and Hospital Fund funderid: 2017JQ0023; 2017‐BSTDJJ04 – fundername: National Nature Science Foundation funderid: 81571318 |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA GWYGA H.X HBH HF~ HGLYW HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES M6Q MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWI RX1 SAMSI SUPJJ SV3 UB1 V8K W8V W99 WBFHL WBKPD WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WWP WXI WXSBR WYISQ XG1 XV2 YCJ ZGI ZZTAW ~IA ~WT AAMMB AAYXX ADXHL AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY AIQQE CITATION NPM K9. 7X8 |
| ID | FETCH-LOGICAL-c3532-7a565c72b0f63c4c4f515ec0dcbb8918fa7f1475bf72c34cc3d898b379f89b093 |
| IEDL.DBID | DR2 |
| ISSN | 0198-6325 1098-1128 |
| IngestDate | Fri Sep 05 14:43:51 EDT 2025 Tue Oct 07 06:24:31 EDT 2025 Mon Jul 21 05:29:51 EDT 2025 Thu Apr 24 22:55:33 EDT 2025 Wed Oct 01 05:53:38 EDT 2025 Wed Jan 22 16:21:40 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | N-methyl-d-aspartate receptor dopamine D2 receptor glycogen synthase kinase 3 beta neurite schizophrenia antipsychotic drugs |
| Language | English |
| License | 2018 Wiley Periodicals, Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3532-7a565c72b0f63c4c4f515ec0dcbb8918fa7f1475bf72c34cc3d898b379f89b093 |
| Notes | Xueqin Song, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China. Email: sxqzhll@126.com ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-5895-2253 |
| PMID | 29785841 |
| PQID | 2148733370 |
| PQPubID | 1016383 |
| PageCount | 18 |
| ParticipantIDs | proquest_miscellaneous_2042749003 proquest_journals_2148733370 pubmed_primary_29785841 crossref_citationtrail_10_1002_med_21512 crossref_primary_10_1002_med_21512 wiley_primary_10_1002_med_21512_MED21512 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | January 2019 2019-01-00 20190101 |
| PublicationDateYYYYMMDD | 2019-01-01 |
| PublicationDate_xml | – month: 01 year: 2019 text: January 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Medicinal research reviews |
| PublicationTitleAlternate | Med Res Rev |
| PublicationYear | 2019 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2015; 78 2010; 11 2007; 104 2012; 120 2013; 3 2010; 468 2006; 32 2004; 27 2015; 72 2013; 67 2011; 61 2004; 9 2005; 62 2004; 3 2008; 32 2008; 105 2001; 49 2008; 33 1997; 280 2013; 7 2008; 100 2010; 26 2005; 102 2015; 86 2011; 71 2017; 77 2010; 113 2005; 73 2011; 63 2016; 41 2010; 4 2007; 17 2010; 33 2004; 44 2009; 66 1976; 261 2010; 35 2007; 282 2005; 353 2015; 122 2006; 59 2007; 90 2012; 39 2012; 38 1992; 31 2016; 17 1996; 16 2007; 12 2011; 8 2011; 132 2012; 109 2006; 355 2004; 55 2018; 19 2016; 6 2010; 49 2011; 306 2013; 214 2011; 94 2010; 212 2010; 177 2005; 10 2002; 71 1998; 78 2001; 158 2009; 106 2015; 35 2002; 58 2002; 59 2013; 23 2002; 51 2008; 9 2008; 7 2011; 11 2008; 79 2011; 14 2011; 17 2005; 27 2009; 49 2001; 106 2017; 117 2016; 77 2005; 25 2013; 18 2006; 60 2013; 16 2017; 39 2000; 57 2005; 30 2011; 25 2014; 9 2012; 69 2003; 84 2008; 60 2001; 98 2007; 27 2015; 1 2012; 141 2015; 15 2015; 6 2014; 92 2015; 5 2006; 12 1995; 15 2006; 11 2017; 22 2006; 7 2008; 13 2011; 35 1999; 4 2014; 84 2007; 54 2014; 83 2015; 7 2012; 76 2008; 283 2009; 1300 2009; 34 2015; 25 2013; 37 2012; 2 2011; 108 2009; 32 2015; 20 2002; 22 2000; 31 2017 2007; 43 2014; 345 1994; 4 2014; 75 e_1_2_10_21_1 e_1_2_10_44_1 e_1_2_10_40_1 e_1_2_10_131_1 e_1_2_10_70_1 e_1_2_10_93_1 e_1_2_10_2_1 e_1_2_10_18_1 e_1_2_10_74_1 e_1_2_10_97_1 e_1_2_10_116_1 e_1_2_10_6_1 e_1_2_10_55_1 e_1_2_10_135_1 e_1_2_10_14_1 e_1_2_10_37_1 e_1_2_10_78_1 e_1_2_10_112_1 e_1_2_10_13_1 e_1_2_10_32_1 e_1_2_10_51_1 e_1_2_10_120_1 e_1_2_10_82_1 e_1_2_10_128_1 e_1_2_10_29_1 e_1_2_10_63_1 e_1_2_10_86_1 e_1_2_10_105_1 e_1_2_10_124_1 e_1_2_10_25_1 e_1_2_10_48_1 e_1_2_10_67_1 e_1_2_10_101_1 e_1_2_10_45_1 e_1_2_10_22_1 e_1_2_10_132_1 e_1_2_10_90_1 e_1_2_10_71_1 e_1_2_10_117_1 e_1_2_10_94_1 e_1_2_10_52_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_75_1 e_1_2_10_113_1 e_1_2_10_136_1 e_1_2_10_38_1 e_1_2_10_98_1 e_1_2_10_79_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_10_1 e_1_2_10_33_1 Domino EF (e_1_2_10_109_1) 2010; 113 Emsley R (e_1_2_10_41_1) 2017; 39 e_1_2_10_121_1 e_1_2_10_60_1 e_1_2_10_106_1 e_1_2_10_129_1 e_1_2_10_83_1 e_1_2_10_64_1 e_1_2_10_102_1 e_1_2_10_125_1 e_1_2_10_49_1 e_1_2_10_87_1 e_1_2_10_26_1 e_1_2_10_68_1 e_1_2_10_23_1 e_1_2_10_46_1 e_1_2_10_69_1 e_1_2_10_42_1 e_1_2_10_110_1 e_1_2_10_91_1 e_1_2_10_72_1 e_1_2_10_95_1 e_1_2_10_118_1 e_1_2_10_4_1 e_1_2_10_53_1 e_1_2_10_137_1 e_1_2_10_16_1 e_1_2_10_39_1 e_1_2_10_76_1 e_1_2_10_99_1 e_1_2_10_114_1 e_1_2_10_8_1 e_1_2_10_57_1 e_1_2_10_133_1 e_1_2_10_58_1 e_1_2_10_34_1 e_1_2_10_11_1 e_1_2_10_30_1 e_1_2_10_119_1 Gareri P (e_1_2_10_5_1) 2014; 9 e_1_2_10_80_1 Perrault G (e_1_2_10_56_1) 1997; 280 e_1_2_10_61_1 e_1_2_10_84_1 e_1_2_10_107_1 e_1_2_10_126_1 e_1_2_10_27_1 e_1_2_10_65_1 e_1_2_10_88_1 e_1_2_10_103_1 e_1_2_10_122_1 e_1_2_10_24_1 e_1_2_10_43_1 e_1_2_10_20_1 e_1_2_10_108_1 e_1_2_10_130_1 e_1_2_10_92_1 e_1_2_10_73_1 e_1_2_10_115_1 e_1_2_10_96_1 e_1_2_10_54_1 e_1_2_10_17_1 e_1_2_10_77_1 e_1_2_10_111_1 e_1_2_10_134_1 e_1_2_10_36_1 e_1_2_10_12_1 e_1_2_10_35_1 e_1_2_10_9_1 e_1_2_10_59_1 e_1_2_10_31_1 e_1_2_10_50_1 e_1_2_10_81_1 e_1_2_10_62_1 e_1_2_10_104_1 e_1_2_10_127_1 e_1_2_10_85_1 e_1_2_10_28_1 e_1_2_10_66_1 e_1_2_10_100_1 e_1_2_10_123_1 e_1_2_10_47_1 e_1_2_10_89_1 |
| References_xml | – volume: 132 start-page: 35 year: 2011 end-page: 41 article-title: Long acting injection versus oral risperidone in first‐episode schizophrenia: Differential impact on white matter myelination trajectory publication-title: Schizophr Res – volume: 33 start-page: 121 year: 2010 end-page: 129 article-title: Structural dynamics of dendritic spines in memory and cognition publication-title: Trends Neurosci – volume: 106 start-page: 19575 year: 2009 end-page: 19580 article-title: Rapid modulation of spine morphology by the 5‐HT2A serotonin receptor through kalirin‐7 signaling publication-title: Proc Natl Acad Sci USA – volume: 84 start-page: 1411 year: 2003 end-page: 1420 article-title: GABA‐induced neurite outgrowth of cerebellar granule cells is mediated by GABA(A) receptor activation, calcium influx and CaMKII and erk1/2 pathways publication-title: J Neurochem – volume: 71 start-page: 877 year: 2002 end-page: 892 article-title: Neuregulin 1 and susceptibility to schizophrenia publication-title: Am J Hum Genet – volume: 9 start-page: 437 year: 2008 end-page: 452 article-title: Neuregulin 1 in neural development, synaptic plasticity and schizophrenia publication-title: Nat Rev Neurosci – volume: 33 start-page: 1343 year: 2008 end-page: 1353 article-title: The role of Akt‐GSK‐3[beta] signaling and synaptic strength in phencyclidine‐induced neurodegeneration publication-title: Neuropsychopharmacology – volume: 41 start-page: 183 year: 2016 end-page: 192 article-title: Perinatal treatments with the dopamine D(2)‐receptor agonist quinpirole produces permanent D(2)‐receptor supersensitization: A model of schizophrenia publication-title: Neurochem Res – volume: 59 start-page: 1189 year: 2006 end-page: 1197 article-title: A review of disrupted‐in‐schizophrenia‐1 (DISC1): Neurodevelopment, cognition, and mental conditions publication-title: Biol Psychiatry – volume: 31 start-page: 320 year: 2000 end-page: 329 article-title: Dysfunctional brain dopamine systems induced by psychotomimetic NMDA‐receptor antagonists and the effects of antipsychotic drugs publication-title: Brain Res Brain Res Rev – volume: 58 start-page: 75 year: 2002 end-page: 81 article-title: Evidence for a decrease in basilar dendrites of pyramidal cells in schizophrenic medial prefrontal cortex publication-title: Schizophr Res – volume: 7 start-page: 1421 year: 2006 end-page: 1434 article-title: Glycogen synthase kinase‐3 (GSK3) in psychiatric diseases and therapeutic interventions publication-title: Curr Drug Targets – volume: 141 start-page: 22 year: 2012 end-page: 28 article-title: Effect of antipsychotic drugs on cortical thickness. A randomized controlled one‐year follow‐up study of haloperidol, risperidone and olanzapine publication-title: Schizophr Res – volume: 78 start-page: 403 year: 2015 end-page: 412 article-title: The effect of antipsychotic treatment on cortical gray matter changes in schizophrenia: Does the class matter? A meta‐analysis and meta‐regression of longitudinal magnetic resonance imaging studies publication-title: Biol Psychiatry – volume: 113 start-page: 678 year: 2010 end-page: 684 article-title: Taming the ketamine tiger. 1965 publication-title: Anesthesiology – volume: 1 start-page: 15067 year: 2015 article-title: Schizophrenia publication-title: Nat Rev Dis Primers – volume: 49 start-page: 327 year: 2009 end-page: 347 article-title: Akt/GSK3 signaling in the action of psychotropic drugs publication-title: Annu Rev Pharmacol Toxicol – volume: 79 start-page: 103 year: 2008 end-page: 110 article-title: DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia publication-title: Biol Psychol – volume: 27 start-page: 43 year: 2005 end-page: 64 article-title: Second‐generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin‐sensitive pathways publication-title: J Mol Neurosci – volume: 105 start-page: 7076 year: 2008 end-page: 7081 article-title: A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition publication-title: Proc Natl Acad Sci USA – volume: 306 start-page: 1359 year: 2011 end-page: 1369 article-title: Efficacy and comparative effectiveness of atypical antipsychotic medications for off‐label uses in adults: A systematic review and meta‐analysis publication-title: JAMA – volume: 73 start-page: 221 year: 2005 end-page: 228 article-title: Meta‐analysis of the time‐course of brain volume reduction in schizophrenia: Implications for pathogenesis and early treatment publication-title: Schizophr Res – volume: 3 start-page: 607 year: 2013 end-page: 614 article-title: Activated CaMKII couples GluN2B and casein kinase 2 to control synaptic NMDA receptors publication-title: Cell Rep – volume: 27 start-page: 379 year: 2004 end-page: 393 article-title: Neuregulin‐1beta induces neurite extension and arborization in cultured hippocampal neurons publication-title: Mol Cell Neurosci – volume: 55 start-page: 1041 year: 2004 end-page: 1045 article-title: Low level of dopaminergic D2 receptor binding in obsessive‐compulsive disorder publication-title: Biol Psychiatry – volume: 355 start-page: 1525 year: 2006 end-page: 1538 article-title: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease publication-title: N Engl J Med – volume: 345 start-page: 1616 year: 2014 end-page: 1620 article-title: A critical time window for dopamine actions on the structural plasticity of dendritic spines publication-title: Science – volume: 27 start-page: S16 issue: Suppl A year: 2005 end-page: S24 article-title: Mechanism of action of antipsychotic drugs: From dopamine D(2) receptor antagonism to glutamate NMDA facilitation publication-title: Clin Ther – volume: 20 start-page: 1037 year: 2015 end-page: 1045 article-title: CRMPs: Critical molecules for neurite morphogenesis and neuropsychiatric diseases publication-title: Mol Psychiatry – volume: 120 start-page: 371 year: 2012 end-page: 384 article-title: Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects publication-title: J Neurochem – volume: 18 start-page: 1185 year: 2013 end-page: 1192 article-title: Molecular evidence of N‐methyl‐ ‐aspartate receptor hypofunction in schizophrenia publication-title: Mol Psychiatry – volume: 3 start-page: 353 year: 2004 end-page: 359 article-title: Magic shotguns versus magic bullets: Selectively non‐selective drugs for mood disorders and schizophrenia publication-title: Nat Rev Drug Discov – volume: 38 start-page: 920 year: 2012 end-page: 926 article-title: NMDA receptor and schizophrenia: A brief history publication-title: Schizophr Bull – volume: 280 start-page: 73 year: 1997 end-page: 82 article-title: Psychopharmacological profile of amisulpride: An antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity publication-title: J Pharmacol Exp Ther – volume: 17 start-page: 470 year: 2011 end-page: 478 article-title: Schizophrenia susceptibility pathway neuregulin 1‐ErbB4 suppresses Src upregulation of NMDA receptors publication-title: Nat Med – volume: 92 start-page: 1000 year: 2014 end-page: 1009 article-title: (5‐HT) regulates neurite outgrowth through 5‐HT1A and 5‐HT7 receptors in cultured hippocampal neurons publication-title: J Neurosci Res – volume: 59 start-page: 663 year: 2002 end-page: 664 article-title: Effects of NMDA receptor antagonists: Implications for the pathophysiology of schizophrenia publication-title: Arch Gen Psychiatry – volume: 2 start-page: e170 year: 2012 article-title: Neurite outgrowth mediated by the heat shock protein Hsp90alpha: A novel target for the antipsychotic drug aripiprazole publication-title: Trans Psychiatry – volume: 49 start-page: 1 year: 2001 end-page: 12 article-title: Antipsychotic treatment induces alterations in dendrite‐ and spine‐associated proteins in dopamine‐rich areas of the primate cerebral cortex publication-title: Biol Psychiatry – volume: 7 start-page: 471 year: 2008 end-page: 472 article-title: Schizophrenia therapy: Beyond atypical antipsychotics publication-title: Nat Rev Drug Discov – volume: 117 start-page: 93 year: 2017 end-page: 105 article-title: Receptor‐stimulated transamidation induces activation of Rac1 and Cdc42 and the regulation of dendritic spines publication-title: Neuropharmacology – volume: 9 start-page: 299 year: 2004 end-page: 307 article-title: Expression analysis of neuregulin‐1 in the dorsolateral prefrontal cortex in schizophrenia publication-title: Mol Psychiatry – volume: 86 start-page: 302 year: 2015 end-page: 323 article-title: Frontal brain volume reduction due to antipsychotic drugs? publication-title: Nervenarzt – volume: 62 start-page: 1205 year: 2005 end-page: 1213 article-title: Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short‐ and long‐term memory publication-title: Arch Gen Psychiatry – volume: 16 start-page: 2157 year: 1996 end-page: 2163 article-title: Interaction between the C terminus of NMDA receptor subunits and multiple members of the PSD‐95 family of membrane‐associated guanylate kinases publication-title: J. Neurosci – volume: 177 start-page: 255 year: 2010 end-page: 260 article-title: Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub‐regions publication-title: Psychiatry Res – volume: 57 start-page: 65 year: 2000 end-page: 73 article-title: Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia publication-title: Arch Gen Psychiatry – volume: 108 start-page: 5795 year: 2011 end-page: 5800 article-title: Impaired NMDA receptor transmission alters striatal synapses and DISC1 protein in an age‐dependent manner publication-title: Proc Natl Acad Sci USA – volume: 17 start-page: 125 year: 2016 end-page: 134 article-title: Linking early‐life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis publication-title: Nat Rev Neurosci – volume: 16 start-page: 1627 year: 2013 end-page: 1636 article-title: Age‐dependent regulation of synaptic connections by dopamine D2 receptors publication-title: Nat Neurosci – volume: 43 start-page: 645 year: 2007 end-page: 654 article-title: Postsynaptic density: A key convergent site for schizophrenia susceptibility factors and possible target for drug development publication-title: Drugs Today (Barc) – volume: 77 start-page: e8 year: 2016 end-page: e13 article-title: Gray matter volumes and treatment response of psychotic symptoms to risperidone in antipsychotic‐naive Alzheimer's disease patients publication-title: J Clin Psychiatry – volume: 27 start-page: 4519 year: 2007 end-page: 4529 article-title: Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: Differential synaptic function in NRG1± knock‐outs compared with wild‐type mice publication-title: J Neurosci – volume: 14 start-page: 285 year: 2011 end-page: 293 article-title: Dendritic spine pathology in neuropsychiatric disorders publication-title: Nat Neurosci – volume: 8 start-page: 114 year: 2011 end-page: 126 article-title: Metabolic and cardiovascular adverse effects associated with antipsychotic drugs publication-title: Nat Rev Endocrinol – volume: 67 start-page: 224 year: 2013 end-page: 234 article-title: Effects of antipsychotic drugs on the expression of synaptic proteins and dendritic outgrowth in hippocampal neuronal cultures publication-title: Synapse – volume: 27 start-page: 12390 year: 2007 end-page: 12395 article-title: Evidence that the BLOC‐1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization publication-title: J Neurosci – volume: 25 start-page: 4974 year: 2005 end-page: 4984 article-title: Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex publication-title: J Neurosci – volume: 34 start-page: 1979 year: 2009 end-page: 1992 article-title: Repeated cocaine administration decreases 5‐HT(2A) receptor‐mediated serotonergic enhancement of synaptic activity in rat medial prefrontal cortex publication-title: Neuropsychopharmacology – volume: 158 start-page: 1367 year: 2001 end-page: 1377 article-title: The emerging role of glutamate in the pathophysiology and treatment of schizophrenia publication-title: Am J Psychiatry – volume: 10 start-page: 877 year: 2005 end-page: 883 article-title: Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics publication-title: Mol Psychiatry – volume: 100 start-page: 270 year: 2008 end-page: 280 article-title: Elevated neuregulin‐1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients publication-title: Schizophr Res – volume: 11 start-page: 539 year: 2010 end-page: 551 article-title: GSK3 signalling in neural development publication-title: Nat Rev Neurosci – volume: 4 start-page: 78 year: 1994 end-page: 96 article-title: Synaptogenesis in the prefrontal cortex of rhesus monkeys publication-title: Cereb Cortex – volume: 468 start-page: 187 year: 2010 end-page: 193 article-title: Rethinking schizophrenia publication-title: Nature – volume: 71 start-page: 311 year: 2011 end-page: 314 article-title: Subtype specific roles of serotonin receptors in the spine formation of cortical neurons in vitro publication-title: Neurosci Res – volume: 17 start-page: 103 year: 2007 end-page: 111 article-title: Autism spectrum disorders: Developmental disconnection syndromes publication-title: Curr Opin Neurobiol – volume: 26 start-page: 363 year: 2010 end-page: 372 article-title: Key role for gene dosage and synaptic homeostasis in autism spectrum disorders publication-title: Trends Genet – volume: 13 start-page: 27 year: 2008 end-page: 35 article-title: Atypical antipsychotic‐induced metabolic side effects: Insights from receptor‐binding profiles publication-title: Mol Psychiatry – volume: 94 start-page: 77 year: 2011 end-page: 90 article-title: Factoring neurotrophins into a neurite‐based pathophysiological model of schizophrenia publication-title: Prog Neurobiol – volume: 109 start-page: 3125 year: 2012 end-page: 3130 article-title: MicroRNA‐132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function publication-title: Proc Natl Acad Sci USA – volume: 63 start-page: 182 year: 2011 end-page: 217 article-title: The physiology, signaling, and pharmacology of dopamine receptors publication-title: Pharmacol Rev – volume: 4 start-page: 418 year: 1999 end-page: 428 article-title: Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia publication-title: Mol Psychiatry – volume: 25 start-page: 505 year: 2015 end-page: 511 article-title: Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin‐dopamine activity modulator: A role for serotonin 5‐HT1A and 5‐HT2A receptors publication-title: Eur Neuropsychopharmacol – volume: 282 start-page: 21497 year: 2007 end-page: 21506 article-title: The p21‐activated kinase 3 implicated in mental retardation regulates spine morphogenesis through a Cdc42‐dependent pathway publication-title: J Biol Chem – volume: 78 start-page: 189 year: 1998 end-page: 225 article-title: Dopamine receptors: From structure to function publication-title: Physiol Rev – volume: 66 start-page: 13 year: 2009 end-page: 20 article-title: Elevated striatal dopamine function linked to prodromal signs of schizophrenia publication-title: Arch Gen Psychiatry – volume: 44 start-page: 749 year: 2004 end-page: 757 article-title: Shrinkage of dendritic spines associated with long‐term depression of hippocampal synapses publication-title: Neuron – volume: 122 start-page: 821 year: 2015 end-page: 831 article-title: Repeated exposure to ketamine‐xylazine during early development impairs motor learning‐dependent dendritic spine plasticity in adulthood publication-title: Anesthesiology – volume: 6 start-page: 10118 year: 2015 article-title: Interneuronal DISC1 regulates NRG1‐ErbB4 signalling and excitatory‐inhibitory synapse formation in the mature cortex publication-title: Nat Commun – volume: 353 start-page: 1209 year: 2005 end-page: 1223 article-title: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia publication-title: N Engl J Med – volume: 15 start-page: 3429 year: 1995 end-page: 3439 article-title: Dopamine D2 receptor mechanisms contribute to age‐related cognitive decline: The effects of quinpirole on memory and motor performance in monkeys publication-title: J Neurosci – volume: 11 start-page: 981 year: 2006 end-page: 983 article-title: Six degrees of separation: On the prior probability that schizophrenia susceptibility genes converge on synapses, glutamate and NMDA receptors publication-title: Mol Psychiatry – volume: 22 start-page: 1205 year: 2017 end-page: 1222 article-title: Endocytosis following dopamine D2 receptor activation is critical for neuronal activity and dendritic spine formation via Rabex‐5/PDGFRbeta signaling in striatopallidal medium spiny neurons publication-title: Mol Psychiatry – volume: 51 start-page: 164 year: 2002 end-page: 171 article-title: Effect of nicotine on quinpirole‐induced checking behavior in rats: Implications for obsessive‐compulsive disorder publication-title: Biol Psychiatry – volume: 61 start-page: 761 year: 2011 end-page: 769 article-title: Differential effects of amisulpride and haloperidol on dopamine D2 receptor‐mediated signaling in SH‐SY5Y cells publication-title: Neuropharmacology – volume: 212 start-page: 329 year: 2010 end-page: 344 article-title: Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole publication-title: Psychopharmacology – volume: 11 start-page: 971 year: 2011 end-page: 987 article-title: Understanding aberrant white matter development in schizophrenia: An avenue for therapy publication-title: Expert Rev Neurother – volume: 35 start-page: 184 year: 2011 end-page: 197 article-title: The acute and chronic effects of combined antipsychotic‐mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes publication-title: Prog Neuropsychopharmacol Biol Psychiatry – volume: 106 start-page: 5 year: 2001 end-page: 14 article-title: Prenatal cocaine exposure produces consistent developmental alterations in dopamine‐rich regions of the cerebral cortex publication-title: Neuroscience – volume: 83 start-page: 27 year: 2014 end-page: 49 article-title: Neuregulin‐ERBB signaling in the nervous system and neuropsychiatric diseases publication-title: Neuron – volume: 32 start-page: 1936 year: 2008 end-page: 1943 article-title: Effect of antipsychotic drugs on brain morphometry. A randomized controlled one‐year follow‐up study of haloperidol, risperidone and olanzapine publication-title: Prog Neuropsychopharmacol Biol Psychiatry – volume: 60 start-page: 132 year: 2006 end-page: 140 article-title: Neuregulin 1 and schizophrenia: Genetics, gene expression, and neurobiology publication-title: Biol Psychiat – volume: 39 start-page: 1 year: 2017 end-page: 10 article-title: Brain volume changes over the first year of treatment in schizophrenia: Relationships to antipsychotic treatment publication-title: Psychol Med – volume: 22 start-page: 6092 year: 2002 end-page: 6105 article-title: D1 dopamine receptor regulation of microtubule‐associated protein‐2 phosphorylation in developing cerebral cortical neurons publication-title: J Neurosci – volume: 60 start-page: 358 year: 2008 end-page: 403 article-title: Antipsychotic drugs: Comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection publication-title: Pharmacol Rev – volume: 7 start-page: 20 year: 2015 article-title: Efficacy and safety of atypical antipsychotic drug treatment for dementia: A systematic review and meta‐analysis publication-title: Alzheimers Res Ther – volume: 31 start-page: 794 year: 1992 end-page: 807 article-title: Neural development is regulated by classical neurotransmitters: Dopamine D2 receptor stimulation enhances neurite outgrowth publication-title: Biol Psychiatry – year: 2017 article-title: The malleable brain: Plasticity of neural circuits and behavior—a review from students to students publication-title: J Neurochem – volume: 39 start-page: 267 year: 2012 end-page: 295 article-title: Glutamatergic synaptic dysregulation in schizophrenia: Therapeutic implications publication-title: Handb Exp Pharmacol – volume: 84 start-page: 1302 year: 2014 end-page: 1316 article-title: A dopamine D2 receptor‐DISC1 protein complex may contribute to antipsychotic‐like effects publication-title: Neuron – volume: 54 start-page: 583 year: 2007 end-page: 597 article-title: The neuregulin‐1 receptor erbB4 controls glutamatergic synapse maturation and plasticity publication-title: Neuron – volume: 5 start-page: e632 year: 2015 article-title: R‐ketamine: A rapid‐onset and sustained antidepressant without psychotomimetic side effects publication-title: Transl Psychiatry – volume: 283 start-page: 17194 year: 2008 end-page: 17204 article-title: Activation of 5‐HT2A/C receptors counteracts 5‐HT1A regulation of n‐methyl‐ ‐aspartate receptor channels in pyramidal neurons of prefrontal cortex publication-title: J Biol Chem – volume: 12 start-page: 824 year: 2006 end-page: 828 article-title: Altered neuregulin 1‐erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia publication-title: Nat Med – volume: 49 start-page: 13 year: 2010 end-page: 23 article-title: Trends in antipsychotic drug use by very young, privately insured children publication-title: J Am Acad Child Adolesc Psychiatry – volume: 12 start-page: 620 year: 2007 end-page: 629 article-title: New genes associated with schizophrenia in neurite formation: A review of cell culture experiments publication-title: Mol Psychiatry – volume: 104 start-page: 19553 year: 2007 end-page: 19558 article-title: Regulation of spine morphology and spine density by NMDA receptor signaling in vivo publication-title: Proc Natl Acad Sci USA – volume: 76 start-page: 175 year: 2012 end-page: 191 article-title: Serotonin in the modulation of neural plasticity and networks: Implications for neurodevelopmental disorders publication-title: Neuron – volume: 72 start-page: 226 year: 2015 end-page: 234 article-title: A multimodal analysis of antipsychotic effects on brain structure and function in first‐episode schizophrenia publication-title: JAMA Psychiatry – volume: 1300 start-page: 58 year: 2009 end-page: 64 article-title: Dystrophic dendrites in prefrontal cortical pyramidal cells of dopamine D1 and D2 but not D4 receptor knockout mice publication-title: Brain Res – volume: 32 start-page: 356 year: 2006 end-page: 365 article-title: Clozapine and haloperidol differentially regulate dendritic spine formation and synaptogenesis in rat hippocampal neurons publication-title: Mol Cell Neurosci – volume: 77 start-page: 419 year: 2017 end-page: 437 article-title: Serotonin receptor 2C regulates neurite growth and is necessary for normal retinal processing of visual information publication-title: Dev Neurobiol – volume: 37 start-page: 1680 year: 2013 end-page: 1691 article-title: Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta‐analysis of longitudinal MRI studies publication-title: Neurosci Biobehav Rev – volume: 6 start-page: 19581 year: 2016 article-title: Olanzapine prevents the PCP‐induced reduction in the neurite outgrowth of prefrontal cortical neurons via NRG1 publication-title: Sci Rep – volume: 11 start-page: 118 year: 2006 end-page: 119 article-title: First in vivo evidence of an NMDA receptor deficit in medication‐free schizophrenic patients publication-title: Mol Psychiatry – volume: 75 start-page: 982 year: 2014 end-page: 990 article-title: Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs‐linking magnetic resonance imaging findings to cellular pathology publication-title: Biol Psychiatry – volume: 23 start-page: 999 year: 2013 end-page: 1009 article-title: Schizophrenia and dopamine receptors publication-title: Eur Neuropsychopharmacol – volume: 15 start-page: 206 year: 2015 end-page: 221 article-title: Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders publication-title: Curr Mol Med – volume: 32 start-page: 485 year: 2009 end-page: 495 article-title: Neurodevelopmental mechanisms of schizophrenia: Understanding disturbed postnatal brain maturation through neuregulin‐1‐ErbB4 and DISC1 publication-title: Trends Neurosci – volume: 69 start-page: 776 year: 2012 end-page: 786 article-title: The nature of dopamine dysfunction in schizophrenia and what this means for treatment publication-title: Arch Gen Psychiatry – volume: 261 start-page: 717 year: 1976 end-page: 719 article-title: Antipsychotic drug doses and neuroleptic/dopamine receptors publication-title: Nature – volume: 9 start-page: 1363 year: 2014 end-page: 1373 article-title: Use of atypical antipsychotics in the elderly: A clinical review publication-title: Clin Interv Aging – volume: 35 start-page: 2942 year: 2015 end-page: 2958 article-title: DBZ regulates cortical cell positioning and neurite development by sustaining the anterograde transport of Lis1 and DISC1 through control of Ndel1 dual‐phosphorylation publication-title: J Neurosci – volume: 98 start-page: 161 year: 2001 end-page: 167 article-title: Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile‐X syndrome: A quantitative examination publication-title: Am J Med Genet – volume: 102 start-page: 17196 year: 2005 end-page: 17201 article-title: The stress‐regulated protein M6a is a key modulator for neurite outgrowth and filopodium/spine formation publication-title: Proc Natl Acad Sci USA – volume: 90 start-page: 76 year: 2007 end-page: 80 article-title: The effects of antipsychotic drugs on GABAA receptor binding depend on period of drug treatment and binding site examined publication-title: Schizophr Res – volume: 4 start-page: 11 year: 2010 article-title: GABAergic control of neurite outgrowth and remodeling during development and adult neurogenesis: General rules and differences in diverse systems publication-title: Front Cell Neurosci – volume: 30 start-page: 1649 year: 2005 end-page: 1661 article-title: The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: A comparison of haloperidol and olanzapine in macaque monkeys publication-title: Neuropsychopharmacology – volume: 7 start-page: 260 year: 2013 article-title: Developmental origins of brain disorders: Roles for dopamine publication-title: Front Cell Neurosci – volume: 20 start-page: 84 year: 2015 end-page: 97 article-title: The neurobiology and treatment of first‐episode schizophrenia publication-title: Mol Psychiatry – volume: 6 start-page: 39209 year: 2016 article-title: Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid antidepressant effect in social defeat stress model: Role of BDNF‐TrkB signaling publication-title: Sci Rep – volume: 19 start-page: 396 year: 2018 end-page: 405 article-title: Decreased 5‐HT2cR and GHSR1a interaction in antipsychotic drug‐induced obesity publication-title: Obes Rev – volume: 35 start-page: 1826 year: 2010 end-page: 1835 article-title: The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2‐selective ex vivo but not in vitro publication-title: Neuropsychopharmacology – volume: 25 start-page: 875 year: 2011 end-page: 887 article-title: Pattern of acute induction of Homer1a gene is preserved after chronic treatment with first‐ and second‐generation antipsychotics: Effect of short‐term drug discontinuation and comparison with Homer1a‐interacting genes publication-title: J Psychopharmacol – volume: 214 start-page: 175 year: 2013 end-page: 180 article-title: Schizophrenia thalamus imaging: Low benzamide binding to dopamine D2 receptors suggests fewer D2Short receptors and fewer presynaptic terminals publication-title: Psychiatry Res – ident: e_1_2_10_53_1 doi: 10.1016/j.psychres.2010.02.009 – ident: e_1_2_10_103_1 doi: 10.1007/978-3-642-25758-2_10 – ident: e_1_2_10_76_1 doi: 10.3389/fncel.2013.00260 – ident: e_1_2_10_3_1 doi: 10.1186/s13195-015-0102-9 – ident: e_1_2_10_48_1 doi: 10.1016/j.schres.2011.06.029 – ident: e_1_2_10_37_1 doi: 10.1016/j.tig.2010.05.007 – ident: e_1_2_10_59_1 doi: 10.1038/sj.mp.4000581 – ident: e_1_2_10_45_1 doi: 10.1016/j.neubiorev.2013.06.001 – ident: e_1_2_10_135_1 doi: 10.3389/fncel.2010.00011 – ident: e_1_2_10_93_1 doi: 10.1523/JNEUROSCI.5029-13.2015 – ident: e_1_2_10_49_1 doi: 10.1586/ern.11.76 – ident: e_1_2_10_61_1 doi: 10.1086/342734 – volume: 9 start-page: 1363 year: 2014 ident: e_1_2_10_5_1 article-title: Use of atypical antipsychotics in the elderly: A clinical review publication-title: Clin Interv Aging – ident: e_1_2_10_101_1 doi: 10.1073/pnas.1012621108 – ident: e_1_2_10_133_1 doi: 10.1111/j.1471-4159.2011.07590.x – ident: e_1_2_10_42_1 doi: 10.1038/sj.npp.1300710 – ident: e_1_2_10_22_1 doi: 10.1038/npp.2009.10 – ident: e_1_2_10_88_1 doi: 10.1016/j.biopsych.2006.03.065 – ident: e_1_2_10_96_1 doi: 10.1073/pnas.0802615105 – ident: e_1_2_10_15_1 doi: 10.1016/j.neuron.2004.11.011 – ident: e_1_2_10_26_1 doi: 10.1074/jbc.M703298200 – ident: e_1_2_10_95_1 doi: 10.2174/1389450110607011421 – ident: e_1_2_10_115_1 doi: 10.1038/sj.npp.1301511 – ident: e_1_2_10_92_1 doi: 10.1146/annurev.pharmtox.011008.145634 – ident: e_1_2_10_51_1 doi: 10.1016/S0006-3223(00)01058-1 – ident: e_1_2_10_113_1 doi: 10.1016/j.mcn.2004.08.001 – ident: e_1_2_10_117_1 doi: 10.1016/j.biopsych.2005.11.002 – ident: e_1_2_10_89_1 doi: 10.1016/j.biopsycho.2007.10.011 – ident: e_1_2_10_114_1 doi: 10.1523/JNEUROSCI.16-07-02157.1996 – ident: e_1_2_10_27_1 doi: 10.1073/pnas.0504262102 – ident: e_1_2_10_4_1 doi: 10.1016/j.jaac.2009.09.003 – ident: e_1_2_10_85_1 doi: 10.1016/j.brainres.2009.09.008 – ident: e_1_2_10_119_1 doi: 10.1016/j.schres.2007.12.474 – ident: e_1_2_10_23_1 doi: 10.1124/pr.107.00107 – ident: e_1_2_10_124_1 doi: 10.1073/pnas.1113793109 – ident: e_1_2_10_16_1 doi: 10.1111/jnc.14107 – ident: e_1_2_10_72_1 doi: 10.1001/archgenpsychiatry.2008.514 – ident: e_1_2_10_34_1 doi: 10.1038/sj.mp.4001886 – ident: e_1_2_10_83_1 doi: 10.1016/0006-3223(92)90311-M – ident: e_1_2_10_30_1 doi: 10.1016/j.tins.2009.05.007 – ident: e_1_2_10_40_1 doi: 10.1016/j.pnpbp.2008.09.020 – ident: e_1_2_10_129_1 doi: 10.1074/jbc.M801713200 – ident: e_1_2_10_31_1 doi: 10.1001/archpsyc.57.1.65 – ident: e_1_2_10_70_1 doi: 10.1038/nrd1346 – ident: e_1_2_10_38_1 doi: 10.1002/1096-8628(20010115)98:2<161::AID-AJMG1025>3.0.CO;2-B – ident: e_1_2_10_47_1 doi: 10.1001/jamapsychiatry.2014.2178 – ident: e_1_2_10_46_1 doi: 10.1038/nrendo.2011.156 – ident: e_1_2_10_79_1 doi: 10.1016/S0006-3223(01)01207-0 – ident: e_1_2_10_107_1 doi: 10.1016/j.clinthera.2005.07.017 – ident: e_1_2_10_9_1 doi: 10.1016/j.biopsych.2015.02.008 – ident: e_1_2_10_127_1 doi: 10.1016/j.neuropharm.2017.01.034 – ident: e_1_2_10_82_1 doi: 10.1016/j.biopsych.2004.01.023 – ident: e_1_2_10_67_1 doi: 10.1002/syn.21634 – volume: 280 start-page: 73 year: 1997 ident: e_1_2_10_56_1 article-title: Psychopharmacological profile of amisulpride: An antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(24)36394-3 – ident: e_1_2_10_128_1 doi: 10.1016/j.neures.2011.07.1824 – ident: e_1_2_10_68_1 doi: 10.1016/j.euroneuro.2013.06.005 – ident: e_1_2_10_137_1 doi: 10.1016/j.schres.2006.11.009 – ident: e_1_2_10_71_1 doi: 10.1038/npp.2010.50 – ident: e_1_2_10_64_1 doi: 10.1038/tp.2012.97 – ident: e_1_2_10_90_1 doi: 10.1016/j.neuron.2014.11.007 – ident: e_1_2_10_75_1 doi: 10.1523/JNEUROSCI.1689-07.2007 – ident: e_1_2_10_81_1 doi: 10.1007/s11064-015-1757-0 – ident: e_1_2_10_125_1 doi: 10.1016/S0165-0173(99)00048-X – ident: e_1_2_10_35_1 doi: 10.1016/S0920-9964(02)00201-3 – ident: e_1_2_10_78_1 doi: 10.1523/JNEUROSCI.15-05-03429.1995 – ident: e_1_2_10_94_1 doi: 10.1038/nrn2870 – ident: e_1_2_10_20_1 doi: 10.1038/mp.2016.200 – ident: e_1_2_10_55_1 doi: 10.1016/j.pnpbp.2010.10.025 – ident: e_1_2_10_84_1 doi: 10.1016/S0306-4522(01)00256-1 – ident: e_1_2_10_91_1 doi: 10.1152/physrev.1998.78.1.189 – ident: e_1_2_10_99_1 doi: 10.2174/1566524015666150330143008 – ident: e_1_2_10_54_1 doi: 10.1177/0269881109358199 – ident: e_1_2_10_73_1 doi: 10.1038/261717a0 – volume: 39 start-page: 1 year: 2017 ident: e_1_2_10_41_1 article-title: Brain volume changes over the first year of treatment in schizophrenia: Relationships to antipsychotic treatment publication-title: Psychol Med – ident: e_1_2_10_13_1 doi: 10.1038/nn.2741 – ident: e_1_2_10_57_1 doi: 10.1385/JMN:27:1:043 – ident: e_1_2_10_58_1 doi: 10.1016/j.mcn.2006.05.007 – ident: e_1_2_10_74_1 doi: 10.1038/sj.mp.4001682 – ident: e_1_2_10_87_1 doi: 10.1001/archpsyc.62.11.1205 – ident: e_1_2_10_97_1 doi: 10.1038/sj.mp.4001751 – ident: e_1_2_10_29_1 doi: 10.1016/j.schres.2004.05.014 – ident: e_1_2_10_131_1 doi: 10.1111/obr.12638 – ident: e_1_2_10_104_1 doi: 10.1038/nrn.2015.19 – ident: e_1_2_10_120_1 doi: 10.1038/sj.mp.4001434 – ident: e_1_2_10_8_1 doi: 10.1056/NEJMoa061240 – ident: e_1_2_10_11_1 doi: 10.1038/nature09552 – ident: e_1_2_10_36_1 doi: 10.1016/j.conb.2007.01.009 – ident: e_1_2_10_105_1 doi: 10.1001/archpsyc.59.7.663 – ident: e_1_2_10_63_1 doi: 10.1176/appi.ajp.158.9.1367 – ident: e_1_2_10_14_1 doi: 10.1016/j.tins.2010.01.001 – ident: e_1_2_10_108_1 doi: 10.1097/ALN.0000000000000579 – ident: e_1_2_10_33_1 doi: 10.1358/dot.2007.43.9.1088821 – ident: e_1_2_10_110_1 doi: 10.1038/tp.2015.136 – ident: e_1_2_10_62_1 doi: 10.1523/JNEUROSCI.4314-06.2007 – ident: e_1_2_10_111_1 doi: 10.1016/j.neuron.2014.06.007 – ident: e_1_2_10_134_1 doi: 10.1002/jnr.23390 – ident: e_1_2_10_100_1 doi: 10.1038/nm1418 – ident: e_1_2_10_122_1 doi: 10.1038/ncomms10118 – ident: e_1_2_10_102_1 doi: 10.1073/pnas.0704031104 – ident: e_1_2_10_112_1 doi: 10.1016/j.celrep.2013.02.011 – ident: e_1_2_10_50_1 doi: 10.1016/j.neuropharm.2011.05.022 – ident: e_1_2_10_132_1 doi: 10.1002/dneu.22391 – ident: e_1_2_10_77_1 doi: 10.1124/pr.110.002642 – ident: e_1_2_10_21_1 doi: 10.1038/nm.2315 – ident: e_1_2_10_6_1 doi: 10.1038/sj.mp.4002066 – ident: e_1_2_10_65_1 doi: 10.1016/j.euroneuro.2015.01.014 – ident: e_1_2_10_17_1 doi: 10.1016/j.pneurobio.2011.04.003 – ident: e_1_2_10_106_1 doi: 10.1093/schbul/sbs076 – ident: e_1_2_10_28_1 doi: 10.1038/mp.2014.66 – ident: e_1_2_10_123_1 doi: 10.1038/mp.2015.77 – ident: e_1_2_10_116_1 doi: 10.1038/nrn2392 – ident: e_1_2_10_19_1 doi: 10.1038/nn.3542 – ident: e_1_2_10_118_1 doi: 10.1016/j.neuron.2007.03.028 – volume: 113 start-page: 678 year: 2010 ident: e_1_2_10_109_1 article-title: Taming the ketamine tiger. 1965 publication-title: Anesthesiology doi: 10.1097/ALN.0b013e3181ed09a2 – ident: e_1_2_10_126_1 doi: 10.1073/pnas.0905884106 – ident: e_1_2_10_130_1 doi: 10.1016/j.neuron.2012.09.013 – ident: e_1_2_10_136_1 doi: 10.1046/j.1471-4159.2003.01638.x – ident: e_1_2_10_10_1 doi: 10.1016/j.biopsych.2013.09.012 – ident: e_1_2_10_44_1 doi: 10.1007/s00115-014-4027-5 – ident: e_1_2_10_98_1 doi: 10.1038/mp.2012.137 – ident: e_1_2_10_18_1 doi: 10.1126/science.1255514 – ident: e_1_2_10_52_1 doi: 10.1007/s00213-010-1954-0 – ident: e_1_2_10_60_1 doi: 10.1038/srep19581 – ident: e_1_2_10_80_1 doi: 10.1016/j.pscychresns.2013.09.013 – ident: e_1_2_10_25_1 doi: 10.1038/nrd2571 – ident: e_1_2_10_69_1 doi: 10.1001/archgenpsychiatry.2012.169 – ident: e_1_2_10_121_1 doi: 10.1523/JNEUROSCI.1086-05.2005 – ident: e_1_2_10_32_1 doi: 10.1093/cercor/4.1.78 – ident: e_1_2_10_12_1 doi: 10.1038/nrdp.2015.67 – ident: e_1_2_10_24_1 doi: 10.1038/sj.mp.4001985 – ident: e_1_2_10_66_1 doi: 10.1038/srep39209 – ident: e_1_2_10_39_1 doi: 10.1016/j.schres.2012.07.014 – ident: e_1_2_10_43_1 doi: 10.4088/JCP.14m09740 – ident: e_1_2_10_2_1 doi: 10.1001/jama.2011.1360 – ident: e_1_2_10_86_1 doi: 10.1523/JNEUROSCI.22-14-06092.2002 – ident: e_1_2_10_7_1 doi: 10.1056/NEJMoa051688 |
| SSID | ssj0011513 |
| Score | 2.4224453 |
| SecondaryResourceType | review_article |
| Snippet | Although antipsychotic drugs are mainly used for treating schizophrenia, they are widely used for treating various psychiatric diseases in adults, the elderly,... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 386 |
| SubjectTerms | antipsychotic drugs Antipsychotics dopamine D2 receptor Drugs glycogen synthase kinase 3 beta Mental competency neurite N‐methyl‐d‐aspartate Psychosis Psychotropic drugs receptor Schizophrenia Synapses |
| Title | Effects of antipsychotic drugs on neurites relevant to schizophrenia treatment |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fmed.21512 https://www.ncbi.nlm.nih.gov/pubmed/29785841 https://www.proquest.com/docview/2148733370 https://www.proquest.com/docview/2042749003 |
| Volume | 39 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 0198-6325 databaseCode: DR2 dateStart: 19960101 customDbUrl: isFulltext: true eissn: 1098-1128 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0011513 providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JS8UwEB7Ekxf35bkRRcSDfbZN2rR4EhdEUEQUPAglSRsRpU9s30F_vZOk7XMF8VbaKUkzM8k30-QbgC2pdSQDJlADovAYK7gnlKHHk3ki40hKYRP65xfx6Q07u41ux2C_PQvj-CG6hJvxDDtfGwcXstobkYbiYtG36xXOvwGNbTh11VFHIdBxpZExqPZiGkYtq5Af7nVvfl6LvgHMz3jVLjgnU3DXdtXtM3nsD2vZV29fWBz_-S3TMNkAUXLgLGcGxopyFrYvHZP16y65Hh3MqnbJNrkccVy_zsGFYz2uyEAT1M1Dc5jrQZH8ZXiPt0timDIRz1bElGVBvF6TekCqj3v8SLfLfR5uTo6vD0-9pjSDp2hEEZMLBIKKh9LXMVVMMY24qFB-rqRM0iDRguuA8UhqHirKlKJ5kiaS8lQnqfRTugDj5aAsloDwMBZpkQRCcs1YxNBUOMIWwXMRBxid9WCnVVKmGt5yUz7jKXOMy2GGo5fZ0evBZif67Mg6fhJabTWdNf5a4RMM3Cil3O_BRvcYPc38PhFlMRiijClLwkzmtweLzkK6VkIMxhHKBdhZq-ffm8_Oj4_sxfLfRVdgAnFa6jI_qzBevwyLNcRCtVy3Rv8OPR8FBQ |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5ROLQXXm1hedVUFeqBLEnsxInEBfHQ8tgVQovEpYpsJ0YIlEUke4BfzzhOsjxaCfUWxRPZ8Xgy30zsbwB-Sa0D6TGBGhCZw1jGHaEMPZ5MIxkGUooqod8fhL1LdnIVXE3BbnMWxvJDtAk3YxnV99oYuElI70xYQ9FbdCuH9QlmWIhxioFEFy15FEIdWxwZw2onpH7Q8Aq5_k776Gtv9A5ivkaslcs5moM_zWDtTpPb7riUXfX0hsfxf99mHmZrLEr27OJZgKksX4Stc0tm_bhNhpOzWcU22SLnE5rrx68wsMTHBRlpguq5qc9z3SiSPoyv8XZODFkmQtqCmMosCNlLUo5I8XKbH2k3un-Dy6PD4X7PqaszOIoGFGG5QCyouC9dHVLFFNMIjTLlpkrKKPYiLbj2GA-k5r6iTCmaRnEkKY91FEs3pt9hOh_l2TIQ7ociziJPSK4ZCxiuFo7IRfBUhB4GaB343WgpUTV1uamgcZdY0mU_wdlLqtnrwM9W9N7ydfxNaK1RdVKbbIEtGLtRSrnbgc22GY3N_EEReTYao4ypTMJM8rcDS3aJtL34GI8jmvNwsJWi_9190j88qC5WPi76Az73hv2z5Ox4cLoKXxC2xTYRtAbT5cM4W0doVMqNygKeAZMqCSY |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwEB0BlRAX-kGBbaG4VYU4kN0kduJE4lJ1WdFSVqsKJC4osh0bIVAWkeyB_vqO4yQLbZEqblE8kR2PJ34zGb8B-CyNiWTABGpAaI8xzT2hLD2ezBMZR1KKOqB_Mo6Pztj38-h8AQ7aszCOH6ILuFnLqL_X1sD1bW4Gc9ZQ3C369Ya1CC9YlCY2oW_4syOPQqjjiiOjW-3FNIxaXiE_HHSPPt6N_oKYjxFrveWMXsJFO1iXaXLdn1Wyr379weP43Ld5BasNFiVf3OJ5DQu6eAO7E0dmfb9PTudns8p9sksmc5rr-zUYO-LjkkwNQfVcNee5rhTJ72aXeLsgliwTIW1JbGUWhOwVqaakfJjmR7pE97dwNjo8_XrkNdUZPEUjirBcIBZUPJS-ialiihmERlr5uZIySYPECG4CxiNpeKgoU4rmSZpIylOTpNJP6TosFdNCbwLhYSxSnQRCcsNYxHC1cEQuguciDtBB68Feq6VMNdTltoLGTeZIl8MMZy-rZ68HnzrRW8fX8S-hrVbVWWOyJbag70Yp5X4PPnbNaGz2D4oo9HSGMrYyCbPB3x5suCXS9RKiP45oLsDB1op-uvvs5HBYX7z7f9EdWJ4MR9mPb-Pj97CCqC11caAtWKruZnobkVElP9QG8BsvEAiq |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+antipsychotic+drugs+on+neurites+relevant+to+schizophrenia+treatment&rft.jtitle=Medicinal+research+reviews&rft.au=Huang%2C+Xu-Feng&rft.au=Song%2C+Xueqin&rft.date=2019-01-01&rft.eissn=1098-1128&rft.volume=39&rft.issue=1&rft.spage=386&rft_id=info:doi/10.1002%2Fmed.21512&rft_id=info%3Apmid%2F29785841&rft.externalDocID=29785841 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0198-6325&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0198-6325&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0198-6325&client=summon |